Quarterly report [Sections 13 or 15(d)]

Segments

v3.26.3
Segments
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segments

Note 14—Segments

 

The Company has two reportable segments. The legacy segment focuses on the previous endeavors of TNF Pharmaceuticals, Inc. This business segment operates in the clinical-stage pharmaceutical space and is specifically focused on Isomyosamine (formerly MYMD-1). The second and primary segment is focused on the development and eventual application of quantum computing technology. The Company’s chief operating decision maker (“CODM”), who is responsible for evaluating financial performance and allocating resources, is the Executive Chairman of the Board. The accounting policies of the dual segments are the same as those described in the summary of significant accounting policies. The CODM does not use assets to assess the segment. The CODM assesses performance for each segment and decides how to allocate resources based on net operating loss excluding stock-based compensation and warrant issuance expenses. The CODM uses a non-GAAP measure, net of operating loss excluding stock-based compensation and warrant issuance expenses, as the primary measure of operating performance and to monitor the Company’s cash burn and adherence to budget.

 

To date, the Company has not generated any product revenues and has incurred losses and negative cash flows from operations since inception.

 

The following table presents certain financial data for the Company’s two reportable segments and a reconciliation to the Company’s consolidated net loss.

 

      2026       2025       2026       2025  
     

For the Three Months Ended

September 30,

     

For the Nine Months Ended

September 30,

 
      2026       2025       2026       2025  
Sales                        
Pharmaceuticals     -       -       -       -  
Computing Technology     -       -       -       -  
Total Sales     -       -       -       -  
Product Cost of Sales                                
Pharmaceuticals     -       -       -       -  
Computing Technology     -       -       -       -  
Total Cost of Sales     -       -       -       -  
Gross Profit     -       -       -       -  
                                 
Operating Expenses                                
Administrative Expenses                                
Pharmaceuticals     109,757       967,833      

363,001

      2,703,815  
Computing Technology     987,815       -       3,267,012       -  
Total Administrative Expenses     1,097,572       967,833       3,630,013       2,703,815  
Research and Development Expenses                                
Pharmaceuticals     4,074       356,352       28,172       2,775,337  
Computing Technology     379,308       -       1,101,877       -  
Total Research and Development Expenses     383,382       356,352       1,130,049       2,775,337  
Stock Based Compensation                                
Pharmaceuticals     -       -       -       189,490  
Computing Technology     860,667       -       5,343,060       -  
Total Stock Based Compensation     860,667       -       5,343,060       189,490  
Franchise Tax Expense                                
Pharmaceuticals     12,365       200,050       34,306       200,050  
Computing Technology     111,289       -       308,751       -  
Total Franchise Tax Expense     123,654       200,050       343,057       200,050  
Warrant Issuance Expenses                                
Pharmaceuticals     -        264,417       -       264,417  
Computing Technology     -       -       -       -  
Total Warrant Issuance Expenses     -       264,417       -       264,417  
Transaction costs associated with due diligence                                
Pharmaceuticals     -       -       -       -  
Computing Technology     100,000       -       100,000       -  
Total Transaction costs associated with due diligence     100,000       -       100,000       -  
Segment Net Loss                                
Pharmaceuticals     126,196       1,788,652       425,479       6,133,109  
Computing Technology     2,439,079       -       10,120,700       -  
Total Segment Net Loss     2,565,275       1,788,652       10,546,179       6,133,109  
                                 
Reconcilement of Net Loss                                
Adjustments and Reconciling Items                                
Interest and Dividend Income                                
Pharmaceuticals     -       35,955       -       156,042  
Computing Technology     55,477       -       227,442       -  
Total Interest and Dividend Income     55,477       35,955     227,442       156,042
Gain (Loss) on Sales of Marketable Securities                                
Pharmaceuticals     -       -       -       2,176
Computing Technology     24,410       -       55,651       -  
Total Gain (Loss) on Sales of Marketable Securities     24,410       -       55,651       2,176
Unrealized Gain (Loss) on Marketable Securities                                
Pharmaceuticals     -       309       -       (1,435 )-
Computing Technology     2,595       -       (4,695 )     -  
Total Unrealized Gain (Loss) on Marketable Securities     2,595       309       (4,695 )     (1,435 )-
Change in Fair Value of Derivative Liabilities                                
Pharmaceuticals     -       (1,059,000 )     -       244,000  
Computing Technology     1,541,000       -       2,132,000       -  
Total Change in Fair Value of Derivative Liabilities     1,541,000       (1,059,000 )     2,132,000       244,000  
Impairment of Technology License                                
Pharmaceuticals     -       -       -       -  
Computing Technology     -       -       (3,177,999 )     -  
Total Impairment of Technology License     -       -       (3,177,999 )     -  
Total Adjustments and Reconciling Items:                                
Pharmaceuticals     -       (1,022,736 )-     -       400,783-  
Computing Technology     1,623,482       -       (767,601 )     -  
Total Adjustments and Reconciling Items     1,623,482       (1,022,736 )-     (767,601 )     400,783-  
                                 
Consolidated Net Loss:                                
Pharmaceuticals     (126,196 )     (2,811,388 )     (425,479 )     (5,732,326 )
Computing Technology     (815,597 )     -       (10,888,301 )     -  
Consolidated Net Loss     (941,793 )     (2,811,388 )     (11,313,780 )     (5,732,326 )

 

Segment assets are not reviewed by the CODM and, accordingly, asset information is not presented.